Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.

Autor: Eapen RS; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia. Renu.Eapen@petermac.org.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Renu.Eapen@petermac.org.; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia. Renu.Eapen@petermac.org.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia. Renu.Eapen@petermac.org., Williams SG; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Macdonald S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Keam SP; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Lawrentschuk N; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia., Au L; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Hofman MS; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia., Murphy DG; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia., Neeson PJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia. paul.neeson@petermac.org.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. paul.neeson@petermac.org.
Jazyk: angličtina
Zdroj: Nature reviews. Urology [Nat Rev Urol] 2024 Nov; Vol. 21 (11), pp. 676-686. Date of Electronic Publication: 2024 Aug 07.
DOI: 10.1038/s41585-024-00913-8
Abstrakt: High-risk localized prostate cancer remains a lethal disease with high rates of recurrence, metastases and death, despite attempts at curative local treatment including surgery. Disease recurrence is thought to be a result of failure of local control and occult micrometastases. Neoadjuvant strategies before surgery have been effective in many cancers, but, to date, none has worked in this setting for prostate cancer. Prostate-specific membrane antigen (PSMA)-based theranostics is an exciting and rapidly evolving field in prostate cancer. The novel intravenous radionuclide therapy, [ 177 Lu]Lu-PSMA-617 (lutetium PSMA) has been shown to be effective in treating men with metastatic castration-resistant prostate cancer, targeting cells expressing PSMA throughout the body. When given in a neoadjuvant setting, lutetium PSMA might also improve long-term oncological outcomes in men with high-risk localized disease. A component of radiotherapy is potentially an immunogenic form of cancer cell death. Lutetium PSMA could cause cancer cell death, resulting in release of tumour antigens and induction of a tumour-specific systemic immune response. This targeted radioligand treatment has the potential to treat local and systemic tumour sites by directly targeting cells that express PSMA, but might also act indirectly via this systemic immune response. In selected patients, lutetium PSMA could potentially be combined with systemic immunotherapies to augment the antitumour T cell response, and this might produce long-lasting immunity in prostate cancer.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: